You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

Welcome to ADVENT!

What do you want to know about type 2 inflammatory diseases?

No matches

ADVENT is a medical education program designed to advance the understanding of type 2 inflammation. ADVENT is developed in collaboration with over 50 global experts and links the latest science of type 2 inflammation with the clinical experience to improve patient care.

Educational resources

Recently added

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

Dermatology

14 min

expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

Dermatology

14 min

expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

Dermatology

60 min

expert video

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

Dermatology

20 min

Podcast

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

On demand event highlights

3 assets

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.

2 assets

World Anosmia Awareness Day

Explore our educational resources about loss of smell and the role of type 2 inflammation in CRSwNP, featuring expert insights from Profs. Wytske Fokkens and Joaquim Mullol.

Join Profs. Eric Simpson, Stephan Weidinger, and Marjolein de Bruin-Weller for an educational symposium exploring the local and systemic effects of type 2 inflammation in AD and potential benefits of early intervention with regard to disease modification.

6 assets

Early Intervention and Disease Modification in AD: Can We Change the Course of the Disease?

Highlights from the ADVENT educational symposium at EADV 2024 where Professors Eric Simpson, Stephan Weidinger, and Marjolein de Bruin-Weller explored the local and systemic effects of type 2 inflammation in AD and potential benefits of early intervention with regard to disease modification.

2 assets

ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

Join Klaus Rabe, MD, PhD, FERS; Celeste Porsberg, MD, PhD; and Mario Castro, MD, MPH, for a symposium on airway remodeling in severe asthma patients.

10 assets

Emerging Perspectives on the Disease Burden and Management of Children with Atopic Dermatitis

Join Christine Bangert, Mark Boguniewicz and Perla Lansang for an educational symposium on atopic dermatitis (AD) in children, exploring the diagnosis and pathophysiology of AD in children, the life-long effects of uncontrolled disease beyond the skin, and current and emerging therapies.

5 assets

ERS 2024 | Pediatric Severe Asthma: Is Clinical Remission Possible?

Watch as Leonard Bacharier, MD, and Sharon Dell, MD, FRCPC, discuss the concept of clinical remission in pediatric severe asthma.

2 assets

SPD | Shifting Gears: Can Disease Course Be Changed in Patients With Pediatric Atopic Dermatitis?

Drs. Amy Paller and Peter Lio led an educational symposium that investigated atopic dermatitis as a risk factor for the development of food allergies. The speakers also discussed the benefits of early intervention in pediatric atopic dermatitis and the potential for disease modification.

Explore all educational resources

Sign up to ADVENT

ADVENT is a medical education program dedicated to Type 2 Inflammation across multiple therapeutic areas. Registering for ADVENT is free and unlocks unlimited access to exclusive features and a wealth of content relevant to the practice of Dermatology, Pulmonology, Rhinology, and Gastroenterology. Sign up now!

Hear from ADVENT experts

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AlgeriaChange country/region

On demand event highlights

3 assets

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

2 assets

World Anosmia Awareness Day

Explore our educational resources about loss of smell and the role of type 2 inflammation in CRSwNP, featuring expert insights from Profs. Wytske Fokkens and Joaquim Mullol.

6 assets

Early Intervention and Disease Modification in AD: Can We Change the Course of the Disease?

2 assets

ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

Join Klaus Rabe, MD, PhD, FERS; Celeste Porsberg, MD, PhD; and Mario Castro, MD, MPH, for a symposium on airway remodeling in severe asthma patients.

10 assets

Emerging Perspectives on the Disease Burden and Management of Children with Atopic Dermatitis

5 assets

ERS 2024 | Pediatric Severe Asthma: Is Clinical Remission Possible?

Watch as Leonard Bacharier, MD, and Sharon Dell, MD, FRCPC, discuss the concept of clinical remission in pediatric severe asthma.

2 assets

SPD | Shifting Gears: Can Disease Course Be Changed in Patients With Pediatric Atopic Dermatitis?

Explore all educational resources

Welcome to ADVENT!

Educational resources

Recently added

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

Exacerbations Lead to Worsening Lung Function

Role of Type 2 Cytokines in Asthma and COPD

Impact of Exacerbations in COPD

Clinical Manifestations Associated With Airway Remodeling in Asthma

Persistence of AD From Childhood Into Adulthood

Key Treatment Considerations for Management of Atopic Dermatitis in Children

Prevalence of Food Allergy and Other Atopic Comorbidities in Children With AD

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

On demand event highlights

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

World Anosmia Awareness Day

Early Intervention and Disease Modification in AD: Can We Change the Course of the Disease?

ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

Emerging Perspectives on the Disease Burden and Management of Children with Atopic Dermatitis

ERS 2024 | Pediatric Severe Asthma: Is Clinical Remission Possible?

SPD | Shifting Gears: Can Disease Course Be Changed in Patients With Pediatric Atopic Dermatitis?

Sign up to ADVENT

Hear from ADVENT experts

Meet our experts

Katrina Abuabara

Seema Aceves

Alvar Agusti

Paolo Amerio

Peter Arkwright

April Armstrong

Ulrike von Arnim

Dhandapani Ashok

Leonard Bacharier

Claus Bachert

Vibeke Backer

Mona Bafadhel

Christine Bangert

Igor Barjaktarevic

Eulàlia Baselga

Eric Bateman

Lisa Beck

Anna Belloni Fortina

Thomas Bieber

Tilo Biedermann

On demand event highlights

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

World Anosmia Awareness Day

Early Intervention and Disease Modification in AD: Can We Change the Course of the Disease?

ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

Emerging Perspectives on the Disease Burden and Management of Children with Atopic Dermatitis

ERS 2024 | Pediatric Severe Asthma: Is Clinical Remission Possible?

SPD | Shifting Gears: Can Disease Course Be Changed in Patients With Pediatric Atopic Dermatitis?

Recently added

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

Exacerbations Lead to Worsening Lung Function

Role of Type 2 Cytokines in Asthma and COPD

Impact of Exacerbations in COPD

Clinical Manifestations Associated With Airway Remodeling in Asthma

Persistence of AD From Childhood Into Adulthood

Key Treatment Considerations for Management of Atopic Dermatitis in Children

Prevalence of Food Allergy and Other Atopic Comorbidities in Children With AD

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch